A new investigation has raised fresh questions about a bestselling prescription medication to reduce stroke risk in those with the heart rhythm disorder known as atrial fibrillation. Published ...

In response, Boehringer Ingelheim claims that the allegations made by BMJ were reported months ago in the media and have been previously addressed by the company. The company has provided regulators ...

The sometimes-fatal bleeding risk of Pradaxa, the popular anticoagulant and alternative to warfarin, has been a concern to the FDA since the drug was approved in 2010. FDA and clinical reviews have ...

Once again dabigatran (Pradaxa) has raised the wrath of the critics. Several articles and an editorial published today in The BMJ raise more questions and concerns about the drug, which is the first ...

Editor's Note: This post originally appeared at drjohnm.org. Before addressing the article's mistakes, it is laudable that mainstream media emphasizes the notion of weighing risks. All medical ...

NEW YORK, NY (updated) — Legal documents unsealed this week in court reveal that employees at Boehringer Ingelheim were so concerned about a research paper suggesting patients taking dabigatran ...

ST. PAUL, Minn., Oct. 20, 2011 /PRNewswire/ -- Treating patients with the new blood thinning medication dabigatran (Pradaxa®), instead of warfarin results in significantly higher per patient costs and ...

Update: Boehringer Ingelheim released a statement regarding the report in The BMJ. If you take the blood thinner Pradaxa, recent news may have left you concerned about its safety. Pradaxa's ...

One of the things that healthcare service providers need to know about the medicines they prescribe is the safety of the drug. Patients need to be aware of the risks associated with their medications ...

Pradaxa is prescribed to reduce the risk of stroke and embolism, treat deep vein thrombosis and pulmonary embolism, prevent blood clots after hip replacement surgery, and treat venous thromboembolic ...